







an Open Access Journal by MDPI

Discoveries in Targeted Therapies for Melanoma: From Molecular Mechanisms to Therapeutics

Guest Editor:

Dr. Georg Thomas Wondrak

R. Ken Coit College of Pharmacy and UA Cancer Center, The University of Arizona, Tucson, AZ, USA

Deadline for manuscript submissions:

1 November 2024

Message from the Guest Editor

Dear Colleagues,

The majority of skin cancer-related deaths is caused by malignant melanoma, a tumor originating from neural crest-derived melanocytes, and novel molecular strategies for the improved detection and treatment of melanoma are of substantial clinical significance. This Special Issue of *Cancers*, entitled 'Discoveries in Targeted Therapy for Melanoma: From Molecular Mechanisms to Therapeutics', aims at gathering original research and review papers on the current understanding of novel molecular mechanisms and therapeutic opportunities that might benefit melanoma patients in the near future.

Thank you for your research efforts. Please consider contributing to this Special Issue.

Dr. Georg Thomas Wondrak Guest Editor













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us